Ignite Creation Date:
2025-12-24 @ 11:10 PM
Ignite Modification Date:
2026-01-06 @ 4:28 PM
Study NCT ID:
NCT03269669
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-17
First Post:
2017-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-01-23
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2017-08-30
First Submit QC Date:
None
Study First Post Date:
2017-09-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-14
Last Update Post Date:
2025-11-17
Last Update Post Date Type:
ESTIMATED